SymBio Pharmaceuticals Limited
Save
8.20B
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Drug Manufacturers - Specialty & Generic
Industry

SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation.

Similar securities

Based on sector and market capitalization

Report issue